elevATP®,
does it really help with Increased cellular ATP, vitality, exercise energy, and strength?
research showselevATP® is rated C. A 12-week double-blind trial in 25 resistance-trained men found greater gains than placebo in squat and deadlift one-repetition maximum and selected power measures, while an acute study in 20 adults reported increased whole-blood ATP. All positive data, however, are tied to the same branded ingredient and have manufacturer or product-developer links, small male samples, surrogate ATP outcomes, and selective exercise endpoints. No direct trial of general vitality or clinically meaningful fatigue improvement was found, so the proprietary-ingredient ceiling under rule ②-b applies.
ads claimMarketing converts a short-lived whole-blood ATP change into cellular energy and all-day vitality, and selected training outcomes into universal strength enhancement. The actual data concern one 150-mg branded ingredient in small samples of healthy adults and trained men.
Useful facts when choosing a product
- elevATP® is a proprietary blend of trace components derived from ancient peat and polyphenols derived from apple. Evidence for it cannot automatically be transferred to generic apple extract or other peat materials.
- The principal 12-week training trial used 150 mg daily and instructed dosing 45 minutes before exercise on training days. This research dose does not validate every multi-ingredient commercial product.
- The acute signal was measured in whole blood, while plasma ATP did not rise. A whole-blood ATP change is not proof of increased mitochondrial ATP in muscle or improved subjective vitality.
- No major laboratory abnormality was reported in the 25-person training trial, but evidence on long-term safety, interactions, pregnancy, lactation, and chronic disease is inadequate. Product identity and matching branded dose require verification.
What the research actually shows
Joy et al. 2016 gave 150 mg/day of elevATP® or placebo for 12 weeks to 25 resistance-trained men. Squat and deadlift one-repetition maximum and selected vertical-jump measures favored treatment, whereas bench-press strength and several Wingate outcomes were not consistently positive; registration was retrospective. Joy et al. 2015 used the same participant dataset and reported ultrasound muscle-size changes, so it is not an independent replication. Reyes-Izquierdo et al. 2014 reported increased whole-blood ATP after a single dose in 20 adults, but plasma ATP was unchanged and muscle ATP was sampled in only one person. No independent large randomized trial directly assessing general vitality, clinical fatigue, daily function, or competition outcomes was found.
Why this is classified as C (48)
A positive randomized signal for exercise strength and power plus an acute whole-blood ATP signal counts as human efficacy evidence. All positive data are nevertheless concentrated in a small, proprietary, industry-linked evidence base; ATP is a surrogate and general vitality or clinical fatigue has not been tested. Rule ②-b caps the grade at C with 48 points, while limited safety knowledge is recorded separately.
Counterpoint. The same 150-mg ingredient may still assist lower-body training adaptations in healthy trained men. Confirmation requires an independently funded, prospectively registered multicenter trial with prespecified strength, competition-performance, and fatigue outcomes.
Rejudgment record. New verdict — Accepted small positive human trials but applied the maximum-C ceiling under rules ① and ②-b for a proprietary, industry-linked ingredient and surrogate endpoints
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved strength and power during resistance training | C | Selected outcomes were positive in a 25-man branded-ingredient trial, but there is no independent replication and results across measures were mixed. |
| Increased whole-blood or cellular ATP | C | The whole-blood surrogate was positive in 20 adults, but plasma ATP was unchanged and muscle data came from one person. |
| Improved general vitality, fatigue, or sustained energy | D | No direct clinical-outcome trial was found; the claim is inferred only from exercise measures and whole-blood ATP. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Joy JM et al. 2016 | Randomized double-blind placebo-controlled 12-week resistance-training trial | 11 | Authors affiliated with FutureCeuticals and MusclePharm; proprietary ingredient; retrospective registration | One-repetition maximum strength and vertical-jump, bench-press, and Wingate power | Squat, deadlift, and selected vertical-jump outcomes favored treatment, but not all performance measures were consistently positive. | Key direct human efficacy evidence with proprietary-ingredient concentration |
| Reyes-Izquierdo T et al. 2014 | Acute placebo-controlled single-dose sequential crossover study | 1 | FutureCeuticals-linked investigators and proprietary ingredient | Whole-blood and plasma ATP, plus muscle ATP in one participant | Whole-blood ATP rose 40% at 60 minutes and 28% at 120 minutes, but plasma ATP did not rise and muscle data came from one person. | Mechanistic surrogate with major limitations |
| Joy JM et al. 2015 | Body-composition and laboratory analysis from the same 12-week trial | 25 | MusclePharm institute and proprietary branded ingredient | Ultrasound muscle cross-sectional area and thickness, DXA, and laboratory tests | Selected ultrasound muscle outcomes favored treatment, but this was not an independent participant sample. | Supporting evidence, not independent replication |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-18).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] elevATP® x increased cellular ATP, vitality, exercise energy, and strength — Evidence Grade C·48. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/elevatp-cellular-atp-vitality-exercise-energy-strength/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.